
The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs to Phase 1 trials.

The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs to Phase 1 trials.